Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
Trial details
- Registry ID
- NCT05942911
- Phase
- Phase 2
The FDA approved Cannabidiol (CBD) on 25 Jun 2018.
Drug identity checked against registry records
Also recorded as CBD; Epidiolex; Epydiolex
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid ArthritisNCT05942911 | Incannex Healthcare Ltd | Phase 2 | Terminated | 2024-10-28Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2018-06-25Day | Cannabidiol | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA210365", "applicant_as_listed_by_fda": "JAZZ PHARMS RES", "brand_names": ["EPIDIOLEX"], "active_ingredients": ["CANNABIDIOL"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20180625", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |